Vasopressin V1a and V1b receptors: from molecules to physiological systems.
暂无分享,去创建一个
Taka-aki Koshimizu | H. Nonoguchi | T. Koshimizu | A. Tanoue | Kazuaki Nakamura | Kazuaki Nakamura | Nobuaki Egashira | Masami Hiroyama | Hiroshi Nonoguchi | Akito Tanoue | N. Egashira | M. Hiroyama
[1] Maurice Manning,et al. Probing the Existence of G Protein-Coupled Receptor Dimers by Positive and Negative Ligand-Dependent Cooperative Binding , 2006, Molecular Pharmacology.
[2] G. Tsujimoto,et al. Alcohol preference in mice lacking the Avpr1a vasopressin receptor. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.
[3] A. Tanoue,et al. Altered lipid metabolism in vasopressin V1B receptor-deficient mice. , 2009, European journal of pharmacology.
[4] Morton Jj,et al. Vasopressin and hypertension in man. , 1986 .
[5] I. Nabi,et al. Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus. , 2001, Biochemistry.
[6] S. Patel,et al. Critical role of a subdomain of the N-terminus of the V1a vasopressin receptor for binding agonists but not antagonists; functional rescue by the oxytocin receptor N-terminus. , 2000, Biochemistry.
[7] G. Guillon,et al. Vasopressin : a potent autocrine/paracrine regulator of mammal adrenal functions. , 1998, Endocrine research.
[8] K. Kovács,et al. Effects of repeated restraint stress on hypothalamo-pituitary-adrenocortical function in vasopressin deficient Brattleboro rats , 2004, Brain Research Bulletin.
[9] J. Schafer,et al. Regulation of Na+ channels in the cortical collecting duct by AVP and mineralocorticoids. , 1992, Kidney international.
[10] W. Young,et al. Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats. , 1993, Endocrinology.
[11] C. Camerino. Low Sympathetic Tone and Obese Phenotype in Oxytocin‐deficient Mice , 2009, Obesity.
[12] G. Tsujimoto,et al. Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor knockout mice , 2007, Behavioural Brain Research.
[13] M. Thibonnier,et al. Role of the human V1 vasopressin receptor COOH terminus in internalization and mitogenic signal transduction. , 2001, American journal of physiology. Endocrinology and metabolism.
[14] S. Hansson,et al. Reproductive hormones in plasma over the menstrual cycle in primary dysmenorrhea compared with healthy subjects , 2008, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[15] Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity. , 1999, The Journal of clinical endocrinology and metabolism.
[16] K. Nakao,et al. Effects of the neurohypophysial hormones on insulin secretion. , 1967, Endocrinology.
[17] E. D. de Kloet,et al. Neurohypophyseal hormone receptors in the rat thymus, spleen, and lymphocytes. , 1990, Endocrinology.
[18] A single residue (arg46) located within the N-terminus of the V1a vasopressin receptor is critical for binding vasopressin but not peptide or nonpeptide antagonists. , 2002, Molecular endocrinology.
[19] W. Waldhäusl,et al. Insulin production rate, hepatic insulin retention and splanchnic carbohydrate metabolism after oral glucose ingestion in hyperinsulinaemic Type 2 (non-insulin-dependent) diabetes mellitus , 1982, Diabetologia.
[20] V. Locatelli,et al. Central nervous system-acting drugs influencing hypothalamic-pituitary-adrenal axis function. , 2010, Endocrine development.
[21] V. Gross,et al. Control of renal medullary blood flow by vasopressin V1 and V2 receptors. , 1995, The American journal of physiology.
[22] D. Cook,et al. The effects of vasopressin on acute kidney injury in septic shock , 2009, Intensive Care Medicine.
[23] D. Yule,et al. Vasopressin directly closes ATP‐sensitive potassium channels evoking membrane depolarization and an increase in the free intracellular Ca2+ concentration in insulin‐secreting cells. , 1989, The EMBO journal.
[24] E. Tribollet,et al. Binding of the Non-Peptide Vasopressin V1a Receptor Antagonist SR-49059 in the Rat Brain: An in vitro and in vivo Autoradiographic Study , 1999, Neuroendocrinology.
[25] S. Tufik,et al. Suppression of Adrenocorticotrophic Hormone Secretion by Simultaneous Antagonism of Vasopressin 1b and CRH-1 Receptors on Three Different Stress Models , 2007, Neuroendocrinology.
[26] M. Westphal,et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study , 2009 .
[27] E. Frank,et al. The vasopressin system--from antidiuresis to psychopathology. , 2008, European journal of pharmacology.
[28] B. Bohus,et al. Inhibition of centrally-evoked pressor responses by neurohypophyseal peptides and their fragments , 1982, Neuropharmacology.
[29] Andrew H. Bass,et al. Social behavior functions and related anatomical characteristics of vasotocin/vasopressin systems in vertebrates , 2001, Brain Research Reviews.
[30] F. Leri,et al. Involvement of Arginine Vasopressin and V1b Receptor in Heroin Withdrawal and Heroin Seeking Precipitated by Stress and by Heroin , 2008, Neuropsychopharmacology.
[31] E. T. Segura,et al. Repeated (isolation) stress increases tribulin-like activity in the rat , 1989, Cellular and Molecular Neurobiology.
[32] R. Landgraf,et al. Advances in vasopressin and oxytocin : from genes to behaviour to disease , 2008 .
[33] S. Yibchok-anun,et al. Effects of arginine vasopressin and oxytocin on glucagon release from clonal alpha-cell line In-R1-G9: involvement of V1b receptors. , 1998, Life sciences.
[34] C. Auzan,et al. Mechanisms of Cell-surface Rerouting of an Endoplasmic Reticulum-retained Mutant of the Vasopressin V1b/V3 Receptor by a Pharmacological Chaperone* , 2005, Journal of Biological Chemistry.
[35] W. Mason,et al. INOSITOL PHOSPHOLIPID TURNOVER AND INTRACELLULAR Ca2+ RESPONSES TO THYROTROPHIN‐RELEASING HORMONE, GONADOTROPHIN‐RELEASING HORMONE AND ARGININE VASOPRESSIN IN PITUITARY CORTICOTROPH AND SOMATOTROPH ADENOMAS , 1990, Clinical endocrinology.
[36] N. Bucher,et al. Internalization, recycling, and redistribution of vasopressin receptors in rat hepatocytes. , 1985, Journal of Biological Chemistry.
[37] H. Schaff,et al. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. , 1993, Chest.
[38] J. Han,et al. Vasopressin and oxytocin receptors coupled to Ca2+ mobilization in rat inner medullary collecting duct. , 1993, The American journal of physiology.
[39] T. Kawada,et al. Oxytocin receptor-deficient mice developed late-onset obesity , 2008, Neuroreport.
[40] David L. Braff,et al. Information-processing deficits and thought disorder in schizophrenia. , 1994 .
[41] S. Yibchok-anun,et al. Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. , 2002, Metabolism: clinical and experimental.
[42] K. Alberti,et al. THE EFFECT OF VASOPRESSIN INFUSION ON GLUCOSE METABOLISM IN MAN , 1985, Clinical endocrinology.
[43] M. Potegal,et al. Vasopressin receptor blockade in the anterior hypothalamus suppresses aggression in hamsters , 1988, Physiology & Behavior.
[44] V. Boulay,et al. Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors. , 2011, Journal of medicinal chemistry.
[45] L. Young,et al. Association of vasopressin 1a receptor levels with a regulatory microsatellite and behavior , 2005, Genes, brain, and behavior.
[46] D. Gewirtz,et al. Induction of Taurocholate Release from Isolated Rat Hepatocytes in Suspension by α‐Adrenergie Agents and Vasopressin: Implications for Control of Bile Salt Secretion , 1984, Hepatology.
[47] D F Swaab,et al. Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances , 2008, Molecular Psychiatry.
[48] J. Liard. L-NAME antagonizes vasopressin V2-induced vasodilatation in dogs. , 1994, The American journal of physiology.
[49] J. Szmydynger-Chodobska,et al. Multiple Sites of Vasopressin Synthesis in the Injured Brain , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[50] J. Brobeck,et al. Evidence for a Role of the Supraopticohypophyseal System in Regulation of Adrenocorticotropic Secretion , 1954, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[51] R. Hodgson,et al. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression , 2007, Pharmacology Biochemistry and Behavior.
[52] M. Thibonnier,et al. Dynamic interaction of human vasopressin/oxytocin receptor subtypes with G protein-coupled receptor kinases and protein kinase C after agonist stimulation. , 2000, The Journal of biological chemistry.
[53] D. Feifel,et al. The Brattleboro Rat Displays a Natural Deficit in Social Discrimination that is Restored by Clozapine and a Neurotensin Analogue , 2009, Neuropsychopharmacology.
[54] H. Albers,et al. Effect of photoperiod on vasopressin-induced aggression in Syrian hamsters , 2004, Hormones and Behavior.
[55] J W Funder,et al. Studies of the secretion of corticotropin-releasing factor and arginine vasopressin into the hypophysial-portal circulation of the conscious sheep. I. Effect of an audiovisual stimulus and insulin-induced hypoglycemia. , 1989, Neuroendocrinology.
[56] E. Braunwald,et al. The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. , 1956, The Journal of clinical investigation.
[57] Rachel A. Millstein,et al. The acute intoxicating effects of ethanol are not dependent on the vasopressin 1a or 1b receptors , 2006, Neuropeptides.
[58] D. Murphy,et al. What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression , 2007, Behavioural Brain Research.
[59] J. Hilton,et al. Effect of synthetic lysine vasopressin on adrenocortical secretion. , 1959, Science.
[60] K. Fuxe,et al. Dimer-based model for heptaspanning membrane receptors. , 2005, Trends in biochemical sciences.
[61] F. Holsboer,et al. Selective activation of the hypothalamic vasopressinergic system in mice deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids. , 2000, Endocrinology.
[62] K. Tomita,et al. Regulation of V2R transcription by hypertonicity and V1aR-V2R signal interaction. , 2008, American journal of physiology. Renal physiology.
[63] A. Meyer-Lindenberg,et al. Genetic variants in AVPR1A linked to autism predict amygdala activation and personality traits in healthy humans , 2009, Molecular Psychiatry.
[64] A. Kjaer,et al. Impaired histamine- and stress-induced secretion of ACTH and beta-endorphin in vasopressin-deficient Brattleboro rats. , 1993, Neuroendocrinology.
[65] Hyagriv N. Simhan,et al. Prevention of Preterm Delivery , 2007 .
[66] Kaori Sato,et al. V2 Receptor–Mediated Autocrine Role of Somatodendritic Release of AVP in Rat Vasopressin Neurons Under Hypo-Osmotic Conditions , 2011, Science Signaling.
[67] D. Rockey,et al. Terlipressin in acute oesophageal variceal haemorrhage , 2003, Alimentary pharmacology & therapeutics.
[68] A. Green,et al. Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist , 2005, British journal of pharmacology.
[69] J. Granton,et al. Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology , 2003, Critical care.
[70] M. Koch,et al. Deficient Sensorimotor Gating After 6‐Hydroxydopamine Lesion of the Rat medial Prefrontal Cortex is Reversed by Haloperidol , 1994, The European journal of neuroscience.
[71] J. Simms,et al. The N-terminal juxtamembrane segment of the V1a vasopressin receptor provides two independent epitopes required for high-affinity agonist binding and signaling. , 2005, Molecular endocrinology.
[72] R. Lamont,et al. The choice of a tocolytic for the treatment of preterm labor: a critical evaluation of nifedipine versus atosiban , 2007, Expert opinion on investigational drugs.
[73] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2000, Science.
[74] D. Hems,et al. Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver. , 1973, The Biochemical journal.
[75] G. Guillon,et al. Vasopressin receptors in human adrenal medulla and pheochromocytoma. , 1999, The Journal of clinical endocrinology and metabolism.
[76] Larry J. Young,et al. The V1a Vasopressin Receptor Is Necessary and Sufficient for Normal Social Recognition: A Gene Replacement Study , 2005, Neuron.
[77] M. Åkerlund,et al. Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin‐induced uterine contractions , 1997, British journal of obstetrics and gynaecology.
[78] L. Bankir,et al. Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. , 2005, Journal of the American Society of Nephrology : JASN.
[79] M. Goldman,et al. Neonatal lesions of the ventral hippocampal formation disrupt neuroendocrine responses to auditory stress in the adult rat , 2004, Psychoneuroendocrinology.
[80] R. Brouard,et al. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. , 1998, Advances in experimental medicine and biology.
[81] John H. Zhang,et al. Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury , 2011, Neurochemistry International.
[82] J. Burbach,et al. Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. , 2001, Endocrinology.
[83] M. Obinata,et al. Aldosterone requires vasopressin V1a receptors on intercalated cells to mediate acid-base homeostasis. , 2011, Journal of the American Society of Nephrology : JASN.
[84] J. R. Mcneill,et al. Pressor Responsiveness and Cardiovascular Reflex Activity in Spontaneously Hypertensive and Normotensive Rats During Vasopressin Infusion , 1981, Journal of cardiovascular pharmacology.
[85] K. Föhr,et al. Oxytocin at physiological concentrations evokes adrenocorticotropin (ACTH) release from corticotrophs by increasing intracellular free calcium mobilized mainly from intracellular stores. Oxytocin displays synergistic or additive effects on ACTH-releasing factor or arginine vasopressin-induced ACTH s , 1992, Endocrinology.
[86] K. Tomita,et al. Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells. , 2008, American journal of physiology. Renal physiology.
[87] J. R. Mcneill,et al. Vasopressin accelerates protein synthesis in neonatal rat cardiomyocytes , 1999, Molecular and Cellular Biochemistry.
[88] D. Wied,et al. Central Nervous System Effects of the Neurohypophyseal Hormones and Related Peptides , 1993, Frontiers in Neuroendocrinology.
[89] J. Vincent,et al. Physiology and pathophysiology of the vasopressinergic system. , 2008, Best practice & research. Clinical anaesthesiology.
[90] D. Swaab,et al. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. , 1996, Archives of general psychiatry.
[91] J. Montastruc,et al. EFFECTS OF LYSINE‐VASOPRESSIN AND OXYTOCIN ON CENTRAL CARDIOVASCULAR CONTROL , 1982, British journal of pharmacology.
[92] C. Péqueux,et al. Provasopressin expression by breast cancer cells: implications for growth and novel treatment strategies , 2006, Breast Cancer Research and Treatment.
[93] M. Raggenbass. Overview of cellular electrophysiological actions of vasopressin. , 2008, European journal of pharmacology.
[94] Eric Trinquet,et al. Cell surface detection of membrane protein interaction with homogeneous time-resolved fluorescence resonance energy transfer technology. , 2004, Analytical biochemistry.
[95] Marc Leone. Terlipressin or Europressin? , 2009, Critical care.
[96] K. Tabei,et al. Luminal vasopressin modulates transport in the rabbit cortical collecting duct. , 1991, The Journal of clinical investigation.
[97] Q. Cai,et al. Axial heterogeneity of vasopressin-receptor subtypes along the human and mouse collecting duct. , 2007, American journal of physiology. Renal physiology.
[98] K. Momose,et al. Both V(1A) and V(1B) vasopressin receptors deficiency result in impaired glucose tolerance. , 2009, European journal of pharmacology.
[99] Peter Kirsch,et al. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine , 2011, Nature Reviews Neuroscience.
[100] T. Sugimoto,et al. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. , 1994, The Journal of biological chemistry.
[101] J. Coyle,et al. Glutamatergic mechanisms in schizophrenia. , 2003, Annual review of pharmacology and toxicology.
[102] H. Vaudry,et al. The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. , 1996, The Journal of clinical investigation.
[103] T. Jovin,et al. FRET imaging , 2003, Nature Biotechnology.
[104] Graeme Milligan,et al. Allostery at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes , 2010, Pharmacological Reviews.
[105] P. Sawchenko,et al. Reflex control of magnocellular vasopressin and oxytocin secretion , 1991, Trends in Neurosciences.
[106] M. Brownstein,et al. Molecular cloning and expression of a rat Via arginine vasopressin receptor , 1992, Nature.
[107] H. Sadeghi,et al. Phosphorylation and recycling kinetics of G protein-coupled receptors. , 1999, Journal of receptor and signal transduction research.
[108] Charged Extracellular Residues, Conserved throughout a G-protein-coupled Receptor Family, Are Required for Ligand Binding, Receptor Activation, and Cell-surface Expression* , 2006, Journal of Biological Chemistry.
[109] P. Robinson,et al. The biosynthesis and secretion of adrenocorticotropin by the ovine anterior pituitary is predominantly regulated by arginine vasopressin (AVP). Evidence that protein kinase C mediates the action of AVP. , 1990, The Journal of biological chemistry.
[110] R. Álvarez-Buylla,et al. Arginine-vasopressin mediates central and peripheral glucose regulation in response to carotid body receptor stimulation with Na-cyanide. , 2006, Journal of applied physiology.
[111] R. Lemmens‐Gruber,et al. Vasopressin antagonists , 2006, Cellular and Molecular Life Sciences.
[112] B. J. Barber,et al. Vasopressin vascular and reflex effects--a theoretical analysis. , 1983, Progress in brain research.
[113] B. Bannwarth,et al. Placental transfer of SR49059 in the human dually perfused cotyledon in vitro. , 2001, Placenta.
[114] Graeme Milligan,et al. G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. , 2006, Drug discovery today.
[115] D. Swaab,et al. Increased Arginine Vasopressin mRNA Expression in the Human Hypothalamus in Depression: A Preliminary Report , 2006, Biological Psychiatry.
[116] V. Wenzel,et al. San Antonio Vasopressin in Shock Symposium report. , 2010, Resuscitation.
[117] G. Kerkhof,et al. Plasma arginine vasopressin and motor activity in major depression , 1998, Biological Psychiatry.
[118] J. Buckingham. UNDERSTANDING THE ROLE OF VASOPRESSIN IN THE HYPOTHALAMO-PITUITARY ADRENOCORTICAL AXIS , 2009 .
[119] T. Sharma,et al. Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research , 2002, Psychopharmacology.
[120] A. Sanyal,et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. , 2008, Gastroenterology.
[121] W. Young,et al. Cloning of rat ARHGAP4/C1, a RhoGAP family member expressed in the nervous system that colocalizes with the Golgi complex and microtubules. , 2002, Brain research. Molecular brain research.
[122] H. Vaudry,et al. Identification of Amino Acid Residues That Direct Differential Ligand Selectivity of Mammalian and Nonmammalian V1a Type Receptors for Arginine Vasopressin and Vasotocin , 2004, Journal of Biological Chemistry.
[123] R. Jankord,et al. The stimuli-specific role of vasopressin in the hypothalamus-pituitary-adrenal axis response to stress. , 2009, The Journal of endocrinology.
[124] R. Landgraf,et al. An intrinsic vasopressin system in the olfactory bulb is involved in social recognition , 2010, Nature.
[125] G. Griebel,et al. Evidence that the Lateral Septum is Involved in the Antidepressant-Like Effects of the Vasopressin V1b Receptor Antagonist, SSR149415 , 2005, Neuropsychopharmacology.
[126] H. D. Wardener. The Hypothalamus and Hypertension , 2001 .
[127] I. Pávó,et al. Vasopressin pressor receptor-mediated activation of HPA axis by acute ethanol stress in rats. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.
[128] G. Tsujimoto,et al. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach. , 2004, Molecular pharmacology.
[129] Jan Born,et al. Sniffing neuropeptides: a transnasal approach to the human brain , 2002, Nature Neuroscience.
[130] R. Manchester,et al. A radio pulsar with an 8.5-second period that challenges emission models , 1999, Nature.
[131] C. Johnston,et al. Restoration of Suppressed Baroreflex Sensitivity in Rats with Hereditary Diabetes Insipidus (Brattleboro Rats) by Arginine‐Vasopressin and DDAVP , 1983, Circulation research.
[132] L. Bankir,et al. Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension? , 2010, American journal of physiology. Renal physiology.
[133] J. R. Henderson,et al. Immunohistochemical localization of oxytocin and vasopressin in the adrenal glands of rat, cow, hamster and guinea pig , 1987, Cell and Tissue Research.
[134] H. Sadeghi,et al. Arrestin effects on internalization of vasopressin receptors. , 2001, Molecular pharmacology.
[135] E. Schäfer,et al. On the Physiological Action of Extracts of Pituitary Body and certain other Glandular Organs , 1895 .
[136] R. Bataller,et al. Arginine vasopressin induces contraction and stimulates growth of cultured human hepatic stellate cells. , 1997, Gastroenterology.
[137] K. Groom. Pharmacological prevention of prematurity , 2007 .
[138] W. Wilkison,et al. The agouti gene product inhibits lipolysis in human adipocytes via a Ca2+‐dependent mechanism , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[139] S. Angers,et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. , 2000, The Journal of clinical investigation.
[140] K. Catt,et al. Mechanisms of action of corticotropin-releasing factor and other regulators of corticotropin release in rat pituitary cells. , 1983, The Journal of biological chemistry.
[141] G. Tsujimoto,et al. Disruption of the Prepulse Inhibition of the Startle Reflex in Vasopressin V1b Receptor Knockout Mice: Reversal by Antipsychotic Drugs , 2005, Neuropsychopharmacology.
[142] K. Catt,et al. Mechanisms of Action of CRF and Other Regulators of ACTH Release in Pituitary Corticotrophs , 1987, Annals of the New York Academy of Sciences.
[143] A. Marmarou,et al. The modulation of aquaporin-4 by using PKC-activator (phorbol myristate acetate) and V1a receptor antagonist (SR49059) following middle cerebral artery occlusion/reperfusion in the rat. , 2008, Acta neurochirurgica. Supplement.
[144] T. Suda,et al. Lysine vasopressin stimulation of cortisol secretion in patients with adrenocorticotropin-independent macronodular adrenal hyperplasia. , 1995, The Journal of clinical endocrinology and metabolism.
[145] R. Landgraf,et al. Microdialysis administration of vasopressin into the septum improves social recognition in Brattleboro rats , 1994, Physiology & Behavior.
[146] Kyung-sup Kim,et al. Obese Gene Expression Alters the Ability of 30A5 Preadipocytes to Respond to Lipogenic Hormones* , 1996, The Journal of Biological Chemistry.
[147] Didier Rognan,et al. Identification of the Binding Sites of the SR49059 Nonpeptide Antagonist into the V1a Vasopressin Receptor Using Sulfydryl-reactive Ligands and Cysteine Mutants as Chemical Sensors* , 2003, Journal of Biological Chemistry.
[148] J. Buckingham,et al. Effects of naloxone on hypothalamo-pituitary-adrenocortical activity in the rat. , 1986, Neuroendocrinology.
[149] G. Griebel,et al. Blockade of CRF1 or V1b receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression , 2004, Molecular Psychiatry.
[150] J. Genescà,et al. Acute esophageal variceal bleeding: Current strategies and new perspectives. , 2010, World journal of hepatology.
[151] J. Maffrand,et al. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. , 2002, Progress in brain research.
[152] C. S. Gal,et al. Pro-inflammatory role of vasopressin through V 1 b receptors in hapten-1 induced experimental colitis in rodents : implication in IBD 2 3 4 Running head : Vasopressin in experimental colitis 5 6 7 , 2010 .
[153] M. Schambelan,et al. Amelioration of metabolic acidosis with fludrocortisone therapy in hyporeninemic hypoaldosteronism. , 1977, The New England journal of medicine.
[154] F. László,et al. Pharmacology and clinical perspectives of vasopressin antagonists. , 1991, Pharmacological reviews.
[155] W. Young,et al. The role of the arginine vasopressin Avp1b receptor in the acute neuroendocrine action of antidepressants , 2008, Psychoneuroendocrinology.
[156] S. Orr,et al. Sex-specific influences of vasopressin on human social communication , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[157] G. Tsujimoto,et al. Attenuated stress-induced catecholamine release in mice lacking the vasopressin V1b receptor. , 2006, American journal of physiology. Endocrinology and metabolism.
[158] P. Vaitkevicius,et al. Therapeutic Potential of Vasopressin Receptor Antagonists , 2012, Drugs.
[159] W. Young,et al. Pituitary‐Adrenal Response to Acute and Repeated Mild Restraint, Forced Swim and Change in Environment Stress in Arginine Vasopressin Receptor 1b Knockout Mice , 2008, Journal of neuroendocrinology.
[160] A. Diedrich,et al. Vasopressin and blood pressure in humans. , 2000, Hypertension.
[161] Zoe R. Donaldson,et al. Central vasopressin V1a receptor activation is independently necessary for both partner preference formation and expression in socially monogamous male prairie voles. , 2010, Behavioral neuroscience.
[162] F. Antoni. Vasopressinergic Control of Pituitary Adrenocorticotropin Secretion Comes of Age , 1993, Frontiers in Neuroendocrinology.
[163] 尾上 尚志. Endothelium-dependent and -independent responses to vasodilators of isolated dog cerebral arteries , 1989 .
[164] G. Tsujimoto,et al. Decreased susceptibility to salt-induced hypertension in subtotally nephrectomized mice lacking the vasopressin V1a receptor. , 2010, Cardiovascular research.
[165] M. Vaughan. EFFECT OF PITRESSIN ON LIPOLYSIS AND ON PHOSPHORYLASE ACTIVITY IN RAT ADIPOSE TISSUE. , 1964, The American journal of physiology.
[166] H. Sadeghi,et al. A serine cluster prevents recycling of the V2 vasopressin receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[167] N. Swerdlow,et al. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review , 2001, Psychopharmacology.
[168] G. Howell,et al. Vasopressin potentiates corticotropin-releasing hormone-induced insulin release from mouse pancreatic β-cells , 2008, The Journal of endocrinology.
[169] F. Antoni,et al. Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue corticotropin-releasing factor. , 1986, Endocrine reviews.
[170] N. Cotte,et al. Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding. , 2000, European journal of biochemistry.
[171] O. Boss,et al. Direct effects of leptin on brown and white adipose tissue. , 1997, The Journal of clinical investigation.
[172] R. Unger,et al. Novel Form of Lipolysis Induced by Leptin* , 1999, The Journal of Biological Chemistry.
[173] Patrick J. Coles,et al. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. , 2001, Annual review of pharmacology and toxicology.
[174] G. Nussdorfer. Paracrine control of adrenal cortical function by medullary chromaffin cells. , 1996, Pharmacological reviews.
[175] M. Palkovits,et al. The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy , 2006, Neuroscience.
[176] Qiang-sun Zheng,et al. Effects of Arginine Vasopressin on Growth of Rat Cardiac Fibroblasts: Role of V1 Receptor , 2003, Journal of cardiovascular pharmacology.
[177] V. Geenen,et al. Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. , 2004, Endocrine-related cancer.
[178] G. Guillon,et al. Pharmacological characterization of F‐180: a selective human V1a vasopressin receptor agonist of high affinity , 2002, British journal of pharmacology.
[179] J. Schafer. Abnormal regulation of ENaC: syndromes of salt retention and salt wasting by the collecting duct. , 2002, American journal of physiology. Renal physiology.
[180] C. Duijn,et al. A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression , 2003, Molecular Psychiatry.
[181] R. Chesnut,et al. Open-Label Randomized Trial of the Safety and Efficacy of a Single Dose Conivaptan to Raise Serum Sodium in Patients with Traumatic Brain Injury , 2011, Neurocritical care.
[182] J. Brown,et al. Blood pressure in acute and chronic vasopressin excess: studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion. , 1981, The New England journal of medicine.
[183] H. Albers,et al. Role of V1a vasopressin receptors in the control of aggression in Syrian hamsters , 2006, Brain Research.
[184] R. Ebstein,et al. Association between a vasopressin receptor AVPR1A promoter region microsatellite and eating behavior measured by a self-report questionnaire (Eating Attitudes Test) in a family-based study of a nonclinical population. , 2004, The International journal of eating disorders.
[185] G. Gessa,et al. Involvement of arginine vasopressin and V1b receptor in alcohol drinking in Sardinian alcohol-preferring rats. , 2011, Alcoholism, clinical and experimental research.
[186] N. Kasting,et al. Convulsive and hypothermic effects of vasopressin in the brain of the rat. , 1980, Canadian journal of physiology and pharmacology.
[187] A. Yamanaka,et al. Vasopressin Increases Locomotion through a V1a Receptor in Orexin/Hypocretin Neurons: Implications for Water Homeostasis , 2008, The Journal of Neuroscience.
[188] D. Bichet. Nephrogenic diabetes insipidus. , 1994, Advances in chronic kidney disease.
[189] E. Hasser,et al. Area Postrema And Sympathetic Nervous System Effects Of Vasopressin And Angiotensin II , 2000, Clinical and experimental pharmacology & physiology.
[190] G. Tsujimoto,et al. V1a receptor knockout mice exhibit impairment of spatial memory in an eight-arm radial maze , 2004, Neuroscience Letters.
[191] Misao Suzuki,et al. A Tubule Cell Line Established from Transgenic Mice Harboring Temperature‐sensitive Simian Virus 40 Large T‐Antigen Gene , 1991, Japanese journal of cancer research : Gann.
[192] M. Westphal,et al. Vasopressin in critical illness: sometimes even old players leave a lot to discover. Preface. , 2008, Best practice & research. Clinical anaesthesiology.
[193] C. Ferris,et al. Vasopressin/Serotonin Interactions in the Anterior Hypothalamus Control Aggressive Behavior in Golden Hamsters , 1997, The Journal of Neuroscience.
[194] B. Altura. Dose-response relationships for arginine vasopressin and synthetic analogs on three types of rat blood vessels: possible evidence for regional differences in vasopressin receptor sites within a mammal. , 1975, The Journal of pharmacology and experimental therapeutics.
[195] T. Goodwin,et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. , 1994, American journal of obstetrics and gynecology.
[196] M. Maggi,et al. Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea. , 1995, Advances in experimental medicine and biology.
[197] J. Masri,et al. Protein Kinase C Regulates Internal Initiation of Translation of the GATA-4 mRNA following Vasopressin-induced Hypertrophy of Cardiac Myocytes* , 2007, Journal of Biological Chemistry.
[198] J. Du,et al. All three vasopressin receptor sub-types are expressed by small-cell carcinoma. , 1998, Advances in experimental medicine and biology.
[199] W. Young,et al. Vasopressin: Behavioral roles of an “original” neuropeptide , 2008, Progress in Neurobiology.
[200] B. Kobilka. Structural insights into adrenergic receptor function and pharmacology. , 2011, Trends in pharmacological sciences.
[201] G. Vinson,et al. Oxytocin and arginine vasopressin stimulate steroid secretion by the isolated perfused rat adrenal gland , 1987, Neuropeptides.
[202] C. Farquhar,et al. Diagnosis and management of dysmenorrhoea , 2006, BMJ : British Medical Journal.
[203] J. V. van Heerikhuize,et al. Elevated serum oxytocin of the vasopressin-deficient Brattleboro rat is present throughout life and is not sensitive to treatment with vasopressin. , 1988, Acta endocrinologica.
[204] C. Record,et al. CONTROLLED TRIAL OF TERLIPRESSIN ('GLYPRESSIN') VERSUS VASOPRESSIN IN THE EARLY TREATMENT OF OESOPHAGEAL VARICES , 1982, The Lancet.
[205] G. Robertson,et al. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. , 1973, The Journal of clinical investigation.
[206] H. Gainer,et al. Synthesis, transport, and release of posterior pituitary hormones. , 1980, Science.
[207] I. Clarke,et al. Neuroendocrine mechanisms of innate states of attenuated responsiveness of the hypothalamo-pituitary adrenal axis to stress , 2006, Frontiers in Neuroendocrinology.
[208] H. Fujiki,et al. Enhanced glucose tolerance in the Brattleboro rat. , 2011, Biochemical and biophysical research communications.
[209] K. Maršál,et al. The oxytocin antagonist atosiban versus the beta-agonist terbutaline in the treatment of preterm labor. A randomized, double-blind, controlled study. , 2001, Acta obstetricia et gynecologica Scandinavica.
[210] T. Thrasher. Baroreceptor Regulation of Vasopressin and Renin Secretion: Low-Pressure versus High-Pressure Receptors , 1994, Frontiers in Neuroendocrinology.
[211] L. Albizu,et al. Past, present and future of vasopressin and oxytocin receptor oligomers, prototypical GPCR models to study dimerization processes. , 2010, Current opinion in pharmacology.
[212] W. Young,et al. The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. , 2007, Endocrinology.
[213] A. Cools,et al. Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex , 1996, Neuroscience.
[214] E. Rozengurt,et al. Vasopressin stimulation of mouse 3T3 cell growth. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[215] K. Henderson,et al. Vasopressin-induced vasoconstriction: two concentration-dependent signaling pathways. , 2007, Journal of applied physiology.
[216] V. S. Bishop,et al. Effect of vasopressin on baroreflex control of lumbar sympathetic nerve activity and hindquarter resistance. , 1996, The American journal of physiology.
[217] K. Tomita,et al. Physiological effects of vasopressin and atrial natriuretic peptide in the collecting duct. , 2001, Cardiovascular research.
[218] Nancy L Pedersen,et al. Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans , 2008, Proceedings of the National Academy of Sciences.
[219] S. Jordan,et al. Intensive care in adults with congenital heart disease: cost implications of a changing patient population , 2005, Critical Care.
[220] G. Gillies,et al. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin , 1982, Nature.
[221] Eric Reiter,et al. GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling , 2006, Trends in Endocrinology & Metabolism.
[222] M. Shibasaki,et al. VASOPRESSIN STIMULATES THE PRODUCTION OF EXTRACELLULAR MATRIX BY CULTURED RAT MESANGIAL CELLS , 2008, Clinical and experimental pharmacology & physiology.
[223] C. Barberis,et al. Molecular cloning of the receptor for human antidiuretic hormone , 1992, Nature.
[224] R. Dantzer,et al. Modulation of social memory in male rats by neurohypophyseal peptides , 1987, Psychopharmacology.
[225] T. Van Itallie,et al. Glycogenolytic effect of vasopressin in the canine liver. , 1960, The American journal of physiology.
[226] G. Tsujimoto,et al. Vasopressin V1A receptor enhances baroreflex via the central component of the reflex arc. , 2007, European journal of pharmacology.
[227] C. S. Gal,et al. Vasopressin Does Not Mediate Hypersensitivity of the Hypothalamic Pituitary Adrenal Axis during Chronic Stress , 2008, Annals of the New York Academy of Sciences.
[228] R. Hauger,et al. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. , 2006, CNS & neurological disorders drug targets.
[229] G. Tsujimoto,et al. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. , 2004, The Journal of clinical investigation.
[230] D. Rognan,et al. Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors. , 2007, Molecular endocrinology.
[231] M. Caron,et al. Association of β-Arrestin with G Protein-coupled Receptors during Clathrin-mediated Endocytosis Dictates the Profile of Receptor Resensitization* , 1999, The Journal of Biological Chemistry.
[232] K. Allan. Pharmacological prevention of prematurity. , 2007 .
[233] T. Insel,et al. Oxytocin: who needs it? , 2001, Progress in Brain Research.
[234] R. Derijk,et al. Anxious–Retarded Depression: Relation with Plasma Vasopressin and Cortisol , 2003, Neuropsychopharmacology.
[235] Claude D Martin,et al. Clinical review: Vasopressin and terlipressin in septic shock patients , 2004, Critical care.
[236] S. Hamburger,et al. Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. , 1992, Archives of general psychiatry.
[237] T Machii,et al. Acylcarnitine metabolism during fasting and after refeeding. , 1996, Biochemical and biophysical research communications.
[238] M. Creager,et al. Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor. , 1989, The Journal of clinical investigation.
[239] A. O'Carroll,et al. The Vasopressin V1b Receptor Modulates Plasma Corticosterone Responses to Dehydration‐Induced Stress , 2011, Journal of neuroendocrinology.
[240] C. Ferris,et al. Patterns of brain vasopressin receptor distribution associated with social organization in microtine rodents , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[241] D. Jezova,et al. Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats , 2007, Hormones and Behavior.
[242] M. Kurachi,et al. Subchronic phencyclidine administration alters central vasopressin receptor binding and social interaction in the rat , 2003, Brain Research.
[243] Shizuka Murakami,et al. PARTICIPATION OF VASOPRESSIN IN THE DEVELOPMENT OF CEREBRAL VASOSPASM IN A RAT MODEL OF SUBARACHNOID HAEMORRHAGE , 2004, Clinical and experimental pharmacology & physiology.
[244] S. Lightman,et al. Blockade of the V(1b) receptor reduces ACTH, but not corticosterone secretion induced by stress without affecting basal hypothalamic-pituitary-adrenal axis activity. , 2008, The Journal of endocrinology.
[245] H. Sadeghi,et al. Transient Phosphorylation of the V1a Vasopressin Receptor* , 1998, The Journal of Biological Chemistry.
[246] J. Ruijter,et al. Vasopressin increases GABAergic inhibition of rat hypothalamic paraventricular nucleus neurons in vitro. , 2000, Journal of neurophysiology.
[247] Mario J. Borgnia,et al. The Aquaporins, Blueprints for Cellular Plumbing Systems* , 1998, The Journal of Biological Chemistry.
[248] W. Wernet,et al. SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.
[249] R. Ramsay,et al. Carnitine acyltransferases and their influence on CoA pools in health and disease. , 2004, Molecular aspects of medicine.
[250] Y. Ishizuka,et al. Involvement of vasopressin V1b receptor in anti-anxiety action of SSRI and SNRI in mice , 2010, Neuroscience Research.
[251] G. Vassart,et al. Non-peptide arginine-vasopressin antagonists: the vaptans , 2008, The Lancet.
[252] J. Warberg,et al. The role of vasopressin in acute cerebral vasospasm. Effect on spasm of a vasopressin antagonist or vasopressin antiserum. , 1988, Journal of neurosurgery.
[253] G. Guillon,et al. Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla. , 1996, Endocrinology.
[254] D. Overstreet,et al. Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat , 2005, Pharmacology Biochemistry and Behavior.
[255] N. Altszuler,et al. Effects of vasopressin on insulin secretion and inositol phosphate production in a hamster beta cell line (HIT). , 1990, Endocrinology.
[256] R. Franceschini,et al. Evaluation of the Secretory Pattern of Plasma Arginine Vasopressin in Stroke Patients , 2001, Cerebrovascular Diseases.
[257] G. Ramsby,et al. Intraarterial vasopressin in the treatment of upper gastrointestinal hemorrhage: a prospective, controlled clinical trial. , 1975, Gastroenterology.
[258] G. Mazzocchi,et al. Evidence that endogenous arginine-vasopressin (AVP) is involved in the maintenance of the growth and steroidogenic capacity of rat adrenal zona glomerulosa , 1993, The Journal of Steroid Biochemistry and Molecular Biology.
[259] W. H. Howell. THE PHYSIOLOGICAL EFFECTS OF EXTRACTS OF THE HYPOPHYSIS CEREBRI AND INFUNDIBULAR BODY , 1898, The Journal of experimental medicine.
[260] M. Shoham,et al. A molecular model of agonist and nonpeptide antagonist binding to the human V(1) vascular vasopressin receptor. , 2000, The Journal of pharmacology and experimental therapeutics.
[261] W. Engeland,et al. Neural circuitry in the regulation of adrenal corticosterone rhythmicity , 2005, Endocrine.
[262] A. Tanoue,et al. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. , 2007, Endocrinology.
[263] R. Hauger,et al. International Union of Pharmacology. XXXVI. Current Status of the Nomenclature for Receptors for Corticotropin-Releasing Factor and Their Ligands , 2003, Pharmacological Reviews.
[264] K. Kikuchi,et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. , 2000, European journal of pharmacology.
[265] J. Simms,et al. Systematic analysis of the entire second extracellular loop of the V(1a) vasopressin receptor: key residues, conserved throughout a G-protein-coupled receptor family, identified. , 2007, The Journal of biological chemistry.
[266] R. Acher,et al. The Neurohypophysial Endocrine Regulatory Cascade: Precursors, Mediators, Receptors, and Effectors , 1995, Frontiers in Neuroendocrinology.
[267] N. A. Popova,et al. Reduced Walker 256 carcinosarcoma growth in vasopressin-deficient Brattleboro rats , 2010, Tumor Biology.
[268] G. Griebel,et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[269] G. Aguilera. Corticotropin Releasing Hormone, Receptor Regulation and the Stress Response , 1998, Trends in Endocrinology & Metabolism.
[270] M. Manning,et al. Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges. , 2007, Biochemical Society transactions.
[271] G. Nussdorfer,et al. Arginin-vasopressin regulates proliferative activity of the regenerating rat adrenal cortex. , 2005, International Journal of Molecular Medicine.
[272] R. Bridges,et al. Arginine vasopressin V1a receptor antagonist impairs maternal memory in rats , 2008, Physiology & Behavior.
[273] R. McIntyre,et al. Discontinued psychiatric drugs in 2008 , 2009, Expert opinion on investigational drugs.
[274] V. Wiegant,et al. Plasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression , 1997, Neuropsychopharmacology.
[275] T. Durroux. Principles: a model for the allosteric interactions between ligand binding sites within a dimeric GPCR. , 2005, Trends in pharmacological sciences.
[276] E. Gould,et al. Fatherhood affects dendritic spines and vasopressin V1a receptors in the primate prefrontal cortex , 2006, Nature Neuroscience.
[277] W. Young,et al. Attenuated Stress Response to Acute Lipopolysaccharide Challenge and Ethanol Administration in Vasopressin V1b Receptor Knockout Mice , 2007, Journal of neuroendocrinology.
[278] Y. Arsenijévic,et al. Vasopressin binding sites in the central nervous system: distribution and regulation. , 1998, Progress in brain research.
[279] H. Marston,et al. Characterization of a novel and selective V1B receptor antagonist. , 2008, Progress in brain research.
[280] B. Mouillac,et al. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. , 2003, Molecular endocrinology.
[281] D. Devost,et al. Identification of dimeric and oligomeric complexes of the human oxytocin receptor by co-immunoprecipitation and bioluminescence resonance energy transfer. , 2003, Journal of molecular endocrinology.
[282] C. Johnston,et al. Vasopressin in circulatory control and hypertension. , 1985, Journal of hypertension.
[283] A. F. Muller,et al. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. , 1986, Molecular pharmacology.
[284] B. Walker. Evidence for a vasodilatory effect of vasopressin in the conscious rat. , 1986, The American journal of physiology.
[285] G. Drews,et al. Mechanisms of the stimulation of insulin release by arginine-vasopressin in normal mouse islets. , 1990, The Journal of biological chemistry.
[286] A. Náray-Fejes-Tóth,et al. Minealocorticoid receptors and 11 beta-steroid dehydrogenase activity in renal principal and intercalated cells. , 1994, The American journal of physiology.
[287] Y. Mori,et al. Structure of the Rat V1a Vasopressin Receptor Gene and Characterization of Its Promoter Region and Complete cDNA Sequence of the 3′-End (*) , 1995, The Journal of Biological Chemistry.
[288] D. Treit,et al. Dissociation of the anxiolytic-like effects of Avpr1a and Avpr1b receptor antagonists in the dorsal and ventral hippocampus , 2008, Neuropeptides.
[289] J. Nakano. Cardiovascular actions of vasopressin. , 1973, Japanese circulation journal.
[290] E. Tribollet,et al. Vasopressin and oxytocin receptors in the central nervous system. , 1996, Critical reviews in neurobiology.
[291] M. Burghammer,et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.
[292] L. Albizu,et al. Differential Coupling of the Vasopressin V1b Receptor through Compartmentalization within the Plasma Membrane , 2009, Molecular Pharmacology.
[293] Allan E. Johnson,et al. Localization and characterization of vasopressin binding sites in the rat brain using an iodinated linear AVP antagonist , 1993, Brain Research.
[294] F. Endo,et al. Hyperammonaemia in V1a vasopressin receptor knockout mice caused by the promoted proteolysis and reduced intrahepatic blood volume , 2007, The Journal of physiology.
[295] D. Cabrol,et al. Treatment of preterm labor with the oxytocin antagonist atosiban: a double-blind, randomized, controlled comparison with salbutamol. , 2001, European journal of obstetrics, gynecology, and reproductive biology.
[296] J. Liard,et al. Vasopressin in cardiovascular control: role of circulating vasopressin. , 1984, Clinical science.
[297] I. Neumann,et al. Vasopressin released within the central amygdala promotes maternal aggression , 2010, The European journal of neuroscience.
[298] M. Kurachi,et al. NC-1900, an arginine–vasopressin analogue, ameliorates social behavior deficits and hyperlocomotion in MK-801-treated rats: Therapeutic implications for schizophrenia , 2005, Brain Research.
[299] P. Leung,et al. Vasopressin rapidly stimulates phosphatidic acid‐phosphatidylinositol turnover in rat anterior pituitary cells , 1985, FEBS letters.
[300] K. Davis,et al. Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.
[301] Michel Bouvier,et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. , 2005, Journal of the American Society of Nephrology : JASN.
[302] B. McEwen. General introduction to vasopressin and oxytocin: structure/metabolism, evolutionary aspects, neural pathway/receptor distribution, and functional aspects relevant to memory processing. , 2004, Advances in Pharmacology.
[303] C. Ferris,et al. Testosterone facilitates aggression by modulating vasopressin receptors in the hypothalamus , 1996, Physiology & Behavior.
[304] A. Tanoue. New topics in vasopressin receptors and approach to novel drugs: effects of vasopressin receptor on regulations of hormone secretion and metabolisms of glucose, fat, and protein. , 2009, Journal of pharmacological sciences.
[305] A. Cowley,et al. Role of vasopressin in cardiovascular regulation. , 1983, Federation proceedings.
[306] J Hoflack,et al. The Binding Site of Neuropeptide Vasopressin V1a Receptor , 1995, The Journal of Biological Chemistry.
[307] P. Houillier,et al. A role for Rhesus factor Rhcg in renal ammonium excretion and male fertility , 2008, Nature.
[308] E. Ginns,et al. Vasopressin V1b receptor knockout reduces aggressive behavior in male mice , 2002, Molecular Psychiatry.
[309] P. L. Munson,et al. Studies on the mechanism of stimulation of ACTH secretion with the aid of morphine as a blocking agent. , 1955, Endocrinology.
[310] F. Endo,et al. Hypermetabolism of fat in V1a vasopressin receptor knockout mice. , 2007, Molecular endocrinology.
[311] C. Trandafir,et al. Enhanced reactivity to vasopressin in rat basilar arteries during vasospasm after subarachnoid hemorrhage. , 2005, European journal of pharmacology.
[312] M. Oz,et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. , 1997, Critical care medicine.
[313] R. Hodgson,et al. Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior , 2009, Psychopharmacology.
[314] L. Filaretova,et al. Age-dependent role of vasopressin in susceptibility of gastric mucosa to indomethacin-induced injury , 2010, Regulatory Peptides.
[315] T. Laudański,et al. The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor , 2005, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[316] G. Gillies,et al. Corticotrophin releasing factor may be modulated vasopressin , 1979, Nature.
[317] W. Russell,et al. Vasopressin modulates liver regeneration in the Brattleboro rat. , 1983, The American journal of physiology.
[318] W. Armstrong. CHAPTER 15 – Hypothalamic Supraoptic and Paraventricular Nuclei , 2004 .
[319] R. Dhar,et al. A Bolus of Conivaptan Lowers Intracranial Pressure in a Patient with Hyponatremia after Traumatic Brain Injury , 2011, Neurocritical care.
[320] W. Kuenzel,et al. Heterooligomerization between vasotocin and corticotropin-releasing hormone (CRH) receptors augments CRH-stimulated 3',5'-cyclic adenosine monophosphate production. , 2007, Molecular endocrinology.
[321] M. Bouvier,et al. Receptor activity‐independent recruitment of βarrestin2 reveals specific signalling modes , 2004, The EMBO journal.
[322] B. Dunning,et al. Actions of neurohypophysial peptides on pancreatic hormone release. , 1984, The American journal of physiology.
[323] H. Gutfreund,et al. Enzyme kinetics , 1975, Nature.
[324] Q. Pittman,et al. Central effects of arginine vasopressin on blood pressure in rats. , 1982, Endocrinology.
[325] W. Meyerhof,et al. Mutational analysis and molecular modeling of the nonapeptide hormone binding domains of the [Arg8]vasotocin receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[326] Meriem Semache,et al. Lipolysis and the integrated physiology of lipid energy metabolism. , 2008, Molecular genetics and metabolism.
[327] N. Tinel,et al. Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization , 2008, Nature Methods.
[328] T. Durroux,et al. Pharmacology of Oxytocin and Vasopressin Receptors in the Central and Peripheral Nervous System a , 1992, Annals of the New York Academy of Sciences.
[329] I. James,et al. Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin‐induced dysmenorrhea , 2006, Acta obstetricia et gynecologica Scandinavica.
[330] P. Petit,et al. A Novel C-terminal Motif Is Necessary for the Export of the Vasopressin V1b/V3 Receptor to the Plasma Membrane* , 2005, Journal of Biological Chemistry.
[331] L. Devi,et al. Receptor heteromerization and drug discovery. , 2010, Trends in pharmacological sciences.
[332] P. Casellas,et al. Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells. , 1994, Biochemical pharmacology.
[333] J Hoflack,et al. Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. , 1995, The EMBO journal.
[334] L. Agius,et al. Effects of ciprofibrate and 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate (POCA) on the distribution of carnitine and CoA and their acyl-esters and on enzyme activities in rats. Relation between hepatic carnitine concentration and carnitine acetyltransferase activity. , 1988, The Biochemical journal.
[335] J. Javitch,et al. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. , 2010, Nature chemical biology.
[336] A. Marmarou,et al. Modulation of AQP4 expression by the selective V1a receptor antagonist, SR49059, decreases trauma-induced brain edema. , 2008, Acta neurochirurgica. Supplement.
[337] M. Imai,et al. Electrophysiological study of luminal and basolateral vasopressin in rabbit cortical collecting duct. , 1995, The American journal of physiology.
[338] P. Sullivan,et al. Arginine Vasopressin Is Associated with Hypercortisolemia and Suicide Attempts in Depression , 1997, Biological Psychiatry.
[339] Ruud M Buijs,et al. Suprachiasmatic GABAergic Inputs to the Paraventricular Nucleus Control Plasma Glucose Concentrations in the Rat via Sympathetic Innervation of the Liver , 2004, The Journal of Neuroscience.
[340] Tomohiko Mori,et al. Downregulation of vasopressin V2 receptor promoter activity via V1a receptor pathway. , 2007, American journal of physiology. Renal physiology.
[341] G. Griebel,et al. Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats , 2006, Psychopharmacology.
[342] R. Lamont,et al. Critical appraisal and clinical utility of atosiban in the management of preterm labor , 2010, Therapeutics and clinical risk management.
[343] B. Wiesner,et al. A dileucine sequence and an upstream glutamate residue in the intracellular carboxyl terminus of the vasopressin V2 receptor are essential for cell surface transport in COS.M6 cells. , 1998, Molecular pharmacology.
[344] G. Guillon,et al. Vasopressin regulates adrenal functions by acting through different vasopressin receptor subtypes. , 1998, Advances in experimental medicine and biology.
[345] Katherine J. Burton,et al. Vasopressin receptor V1a regulates circadian rhythms of locomotor activity and expression of clock-controlled genes in the suprachiasmatic nuclei. , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.
[346] J. Granton,et al. Science Review: Vasopressin and the cardiovascular system part 1 – receptor physiology , 2003, Critical care.
[347] T. Nagasaka,et al. Baroreflexive suppression of heat production and fall in body temperature following peripheral administration of vasopressin in rats. , 1984, The Japanese journal of physiology.
[348] Christian Grillon,et al. Gating and habituation of the startle reflex in schizophrenic patients. , 1992 .
[349] G. Tsujimoto,et al. Insulin hypersensitivity in mice lacking the V1b vasopressin receptor , 2007, The Journal of physiology.
[350] P. Baylis,et al. Plasma Arginine Vasopressin in diabetic ketoacidosis , 1979, Diabetologia.
[351] N. Payet,et al. Adrenal glomerulosa mitotic stimulation by posterior pituitary hormones , 1976, Cell and Tissue Research.
[352] F. Marumo,et al. Immunohistochemical localization of V2 vasopressin receptor along the nephron and functional role of luminal V2 receptor in terminal inner medullary collecting ducts. , 1995, The Journal of clinical investigation.
[353] K. Groom. Preterm labour. Pharmacological prevention of prematurity. , 2007, Best practice & research. Clinical obstetrics & gynaecology.
[354] G. Guillon,et al. Regulation of Adrenocortical Function by Vasopressin , 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[355] Nadia Ferguson-Myrthil. Novel Agents for the Treatment of Hyponatremia: A Review of Conivaptan and Tolvaptan , 2010, Cardiology in review.
[356] Richmond R. Thompson,et al. Nonapeptide mechanisms of social cognition, behavior and species-specific social systems , 2010, Current Opinion in Neurobiology.
[357] H. Gavras,et al. Interaction of the Sympathetic Nervous System with Vasopressin and Renin in the Maintenance of Blood Pressure , 1982, Hypertension.
[358] P. Raskin,et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.
[359] S. Jard,et al. Vasopressin: mechanisms of receptor activation. , 1983, Progress in brain research.
[360] Y. Imai,et al. Cardiovascular depression and stabilization by central vasopressin in rats. , 1990, HYPERTENSION.
[361] Liping Wei,et al. Adrenalectomy enhances the insulin sensitivity of muscle protein synthesis. , 2003, American journal of physiology. Endocrinology and metabolism.
[362] U. Moll,et al. The neuroendocrine thymus , 1988, Histochemistry.
[363] G. Tsujimoto,et al. Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice. , 2007, The Journal of endocrinology.
[364] T. Insel,et al. Increased affiliative response to vasopressin in mice expressing the V1a receptor from a monogamous vole , 1999, Nature.
[365] T. Koshimizu,et al. Vasopressin regulation of blood pressure and volume: findings from V1a receptor-deficient mice. , 2009, Kidney international.
[366] L. Swanson,et al. Immunohistochemical identification of neurons in the paraventricular nucleus of the hypothalamus that project to the medulla or to the spinal cord in the rat , 1982, The Journal of comparative neurology.
[367] Mohamed H. Ahmed,et al. Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists. , 2010, World journal of gastroenterology.
[368] M. Shibasaki,et al. Vasopressin increases type IV collagen production through the induction of transforming growth factor-beta secretion in rat mesangial cells. , 2008, Pharmacological research.
[369] Sangeeta Mehta,et al. Vasopressin versus norepinephrine infusion in patients with septic shock. , 2008, The New England journal of medicine.
[370] O. Melander,et al. Relation between human vasopressin 1a gene variance, fat intake, and diabetes. , 2009, The American journal of clinical nutrition.
[371] Zoe R. Donaldson,et al. Oxytocin, Vasopressin, and the Neurogenetics of Sociality , 2008, Science.
[372] D. Bichet,et al. Molecular biology of hereditary diabetes insipidus. , 2005, Journal of the American Society of Nephrology : JASN.
[373] J. Hobbins,et al. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group. , 2000, American journal of obstetrics and gynecology.
[374] C. Ferris,et al. Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior , 2006, Pharmacology Biochemistry and Behavior.
[375] J. Montani,et al. Hemodynamic Effects of Exogenous and Endogenous Vasopressin at Low Plasma Concentrations in Conscious Dogs , 1980, Circulation research.
[376] L. Young,et al. Viral vector‐mediated gene transfer of the vole V1a vasopressin receptor in the rat septum: improved social discrimination and active social behaviour , 2003, The European journal of neuroscience.
[377] Chien-Nan Lee,et al. Randomized trial of oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of spontaneous preterm labor in Taiwanese women. , 2009, Journal of the Formosan Medical Association = Taiwan yi zhi.
[378] H. Gavras,et al. Does vasopressin sustain blood pressure of normally hydrated healthy volunteers? , 1984, The American journal of physiology.
[379] G. Schütz,et al. Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin–neurophysin II precursor , 1982, Nature.
[380] W. Young,et al. Disruption of the vasopressin 1b receptor gene impairs the attack component of aggressive behavior in mice , 2007, Genes, brain, and behavior.
[381] H. Nisell,et al. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour , 2003, BJOG : an international journal of obstetrics and gynaecology.
[382] D. Devost,et al. Homo‐ and Hetero‐Dimeric Complex Formations of the Human Oxytocin Receptor , 2004, Journal of neuroendocrinology.
[383] G. Makara,et al. Congenital vasopressin deficiency and acute and chronic opiate effects on hypothalamo-pituitary-adrenal axis activity in Brattleboro rats. , 2007, The Journal of endocrinology.
[384] J. T. Shepherd,et al. Vasopressin Causes Endothelium‐Dependent Relaxations of the Canine Basilar Artery , 1984, Circulation research.
[385] W. Young,et al. The vasopressin Avprlb receptor: Molecular and pharmacological studies , 2010, Stress.
[386] C. Belzung,et al. Involvement of vasopressin in affective disorders. , 2008, European journal of pharmacology.
[387] J. B. Murray,et al. Phencyclidine (PCP): A Dangerous Drug, but Useful in Schizophrenia Research , 2002, The Journal of psychology.
[388] G. Griebel,et al. An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders. , 2006, CNS drug reviews.
[389] W. Young,et al. Vasopressin 1a receptor knockout mice have a subtle olfactory deficit but normal aggression , 2007, Genes, brain, and behavior.
[390] J. Clements,et al. Arginine vasopressin (AVP) and AVP-like immunoreactivity in peripheral tissues. , 1986, Endocrine reviews.
[391] G. Owens,et al. Arginine Vasopressin‐Induced Hypertrophy of Cultured Rat Aortic Smooth Muscle Cells , 1989, Hypertension.
[392] Gary Bornstein,et al. Molecular genetic studies of the arginine vasopressin 1a receptor (AVPR1a) and the oxytocin receptor (OXTR) in human behaviour: from autism to altruism with some notes in between. , 2008, Progress in brain research.
[393] R. Oishi,et al. New topics in vasopressin receptors and approach to novel drugs: role of the vasopressin receptor in psychological and cognitive functions. , 2009, Journal of pharmacological sciences.
[394] H. Akashi,et al. Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. , 2007, Interactive cardiovascular and thoracic surgery.
[395] M. Åkerlund,et al. Inhibitory effects of SR 49059 on oxytocin‐and vasopressin‐induced uterine contractions in non‐pregnant women , 2004, Acta obstetricia et gynecologica Scandinavica.
[396] M. Keck,et al. Vasopressin in CSF and plasma in depressed suicide attempters: preliminary results , 2002, European Neuropsychopharmacology.
[397] Manfred Burghammer,et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. , 2007, Nature.
[398] G. Gimpl,et al. The oxytocin receptor system: structure, function, and regulation. , 2001, Physiological reviews.
[399] W. Vale,et al. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin , 1981 .
[400] P. Pothier,et al. On the presence of chromaffin cells in the adrenal cortex: their possible role in adrenocortical function. , 1987, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[401] G. Tsujimoto,et al. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[402] S L Lightman,et al. Emergence of an isolated arginine vasopressin (AVP) response to stress after repeated restraint: a study of both AVP and corticotropin-releasing hormone messenger ribonucleic acid (RNA) and heteronuclear RNA. , 1997, Endocrinology.
[403] A. Yarkov,et al. Arginine-vasopressin in nucleus of the tractus solitarius induces hyperglycemia and brain glucose retention , 2001, Brain Research.
[404] D. Chassard,et al. Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea , 2000, BJOG : an international journal of obstetrics and gynaecology.
[405] D. Swaab,et al. Hypothalamic Vasopressin and Oxytocin mRNA Expression in Relation to Depressive State in Alzheimer’s Disease: A Difference With Major Depressive Disorder , 2009, Journal of neuroendocrinology.
[406] P. Conn,et al. G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo , 2007, Pharmacological Reviews.
[407] H. Vaudry,et al. Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors. , 1993, The Journal of clinical endocrinology and metabolism.
[408] M. Birnbaumer. Vasopressin Receptors , 2000, Trends in Endocrinology & Metabolism.
[409] J. Kreisberg,et al. Arginine vasopressin stimulates mesangial cell proliferation by activating the epidermal growth factor receptor. , 2001, American journal of physiology. Renal physiology.
[410] P. Hamet,et al. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. , 2001, Endocrine reviews.
[411] D. Rockey,et al. Complications and outcomes in chronic liver disease , 2011, Current opinion in gastroenterology.
[412] F. Marumo,et al. Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction. , 1993, The Journal of clinical investigation.
[413] G. Griebel,et al. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. , 2002, The Journal of pharmacology and experimental therapeutics.
[414] E. Hasser,et al. Reflex effect of vasopressin after blockade of V1 receptors in the area postrema. , 1990, Circulation research.
[415] H. Vaudry,et al. Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. , 2006, The Journal of clinical endocrinology and metabolism.
[416] C. Haslett,et al. Targeting V1A‐vasopressin receptors with [Arg6, D‐Trp7,9, NmePhe8]‐substance P (6‐11) identifies a strategy to develop novel anti‐cancer therapies , 2009, British journal of pharmacology.
[417] Philippe Froguel,et al. Disruption of Adiponectin Causes Insulin Resistance and Neointimal Formation* , 2002, The Journal of Biological Chemistry.
[418] M. Craighead,et al. Attenuated Stress Response to Acute Restraint and Forced Swimming Stress in Arginine Vasopressin 1b Receptor Subtype (Avpr1b) Receptor Knockout Mice and Wild-Type Mice Treated with a Novel Avpr1b Receptor Antagonist , 2010, Journal of neuroendocrinology.
[419] Howard Eichenbaum,et al. Vasopressin 1b Receptor Knock-Out Impairs Memory for Temporal Order , 2009, The Journal of Neuroscience.
[420] E. Schiffrin,et al. Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension. , 1997, The Journal of clinical endocrinology and metabolism.
[421] A. Náray-Fejes-Tóth,et al. Distribution of mineralocorticoid and glucocorticoid receptor mRNA along the nephron. , 1993, The American journal of physiology.
[422] L. Branco,et al. Role of L-glutamate in systemic AVP-induced hypothermia. , 2003, Journal of applied physiology.
[423] Xueqian Zhang,et al. Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gαq-mediated cell signaling. , 2011, Circulation.
[424] G. Griebel,et al. AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters , 2005, Pharmacology Biochemistry and Behavior.
[425] H. Vaudry,et al. Vasopressin-responsive adrenocortical tumor in a mild Cushing's syndrome: in vivo and in vitro studies. , 1995, The Journal of clinical endocrinology and metabolism.
[426] W. Maier,et al. Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[427] C. S. Gal,et al. Key amino acids located within the transmembrane domains 5 and 7 account for the pharmacological specificity of the human V1b vasopressin receptor. , 2004, Molecular endocrinology.
[428] F. Marumo,et al. Role of urinary arginine vasopressin in the sodium excretion in patients with chronic renal failure. , 1996, The American journal of the medical sciences.
[429] R. Arban. V1b receptors: new probes for therapy. , 2007, Endocrinology.
[430] I. Bird,et al. Vasopressin stimulates cortisol secretion and phosphoinositide catabolism in cultured bovine adrenal fasciculata/reticularis cells. , 1990, Journal of Molecular Endocrinology.
[431] C. Hoppel,et al. Relationship between acid-soluble carnitine and coenzyme A pools in vivo. , 1980, The Biochemical journal.
[432] S. Gardiner,et al. Differential Cardiovascular Effects of Centrally Administered Vasopressin in Conscious Long Evans and Brattleboro Rats , 1989, Circulation research.
[433] W. Oelkers,et al. Effects of incremental infusions of arginine vasopressin on adrenocorticotropin and cortisol secretion in man. , 1988, The Journal of clinical endocrinology and metabolism.
[434] H. Westphal,et al. Vasopressin receptor 1a-mediated negative regulation of B cell receptor signaling , 2003, Journal of Neuroimmunology.
[435] C. Adler,et al. Effects of Acute Metabolic Stress on the Peripheral Vasopressinergic System in Schizophrenia , 2003, Journal of psychopharmacology.
[436] L. Bankir,et al. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. , 2008, Journal of the American Society of Nephrology : JASN.
[437] Shuyi Wang,et al. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice. , 2007, European journal of pharmacology.
[438] M. Åkerlund. Involvement of oxytocin and vasopressin in the pathophysiology of preterm labor and primary dysmenorrhea. , 2002, Progress in brain research.
[439] A. Tanoue,et al. Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor. , 2007, European journal of pharmacology.
[440] S. Sasaki,et al. Aquaporins in kidney pathophysiology , 2010, Nature Reviews Nephrology.
[441] P. Shilling,et al. Reversal of Sensorimotor Gating Deficits in Brattleboro Rats by Acute Administration of Clozapine and a Neurotensin Agonist, but not Haloperidol: a Potential Predictive Model for Novel Antipsychotic Effects , 2004, Neuropsychopharmacology.
[442] S. Ferguson,et al. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. , 2001, Pharmacological reviews.
[443] S. Alexander,et al. Effect of insulin-induced hypoglycaemia on secretion patterns and rates of corticotrophin-releasing hormone, arginine vasopressin and adrenocorticotrophin in horses. , 1997, The Journal of endocrinology.
[444] M. Thibonnier,et al. Molecular pharmacology of human vasopressin receptors. , 1998, Advances in experimental medicine and biology.
[445] C. Kirk,et al. Rapid stimulation, by vasopressin and adrenaline, of inorganic phosphate incorporation into phosphatidyl inositol in isolated hepatocytes , 1977, FEBS letters.
[446] S. Subburaju,et al. The parvocellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. , 2008, Progress in brain research.
[447] G. Alonso,et al. Hypothalamic vasopressin release and hepatocyte Ca2+ signaling during liver regeneration: an interplay stimulating liver growth and bile flow , 2003 .
[448] S. Hawtin. Pharmacological Chaperone Activity of SR49059 to Functionally Recover Misfolded Mutations of the Vasopressin V1a Receptor* , 2006, Journal of Biological Chemistry.
[449] E. Rozengurt,et al. Phorbol esters and vasopressin stimulate DNA synthesis by a common mechanism , 1980, Nature.
[450] M. Knepper,et al. Control of sodium and potassium transport in the cortical collecting duct of the rat. Effects of bradykinin, vasopressin, and deoxycorticosterone. , 1985, The Journal of clinical investigation.
[451] B. Leventhal,et al. Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism , 2002, Molecular Psychiatry.
[452] M. Bouvier,et al. Roles of G‐protein‐coupled receptor dimerization , 2004, EMBO reports.
[453] S. Lightman,et al. Effect of vasopressin 1b receptor blockade on the hypothalamic-pituitary-adrenal response of chronically stressed rats to a heterotypic stressor. , 2008, The Journal of endocrinology.
[454] Larry J Young,et al. Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout Mice , 2004, Neuropsychopharmacology.
[455] M. Joubert,et al. Aberrant adrenal sensitivity to vasopressin in adrenal tumours associated with subclinical or overt autonomous hypercortisolism: is this explained by an overexpression of vasopressin receptors? , 2008, Clinical endocrinology.
[456] H. D. de Wardener. The hypothalamus and hypertension. , 2001, Physiological reviews.
[457] R. Bridges,et al. Central actions of arginine vasopressin and a V1a receptor antagonist on maternal aggression, maternal behavior, and grooming in lactating rats , 2008, Pharmacology Biochemistry and Behavior.
[458] W. Hsu,et al. Effect of AVP and oxytocin on insulin release: involvement of V1b receptors. , 1995, The American journal of physiology.
[459] Young Vr,et al. Ntau-methylhistidine (3-methylhistidine) and muscle protein turnover: an overview. , 1978 .
[460] J. Elands,et al. Oxytocin-stimulated release of adrenocorticotropin from the rat pituitary is mediated by arginine vasopressin receptors of the V1b type. , 1994, Endocrinology.
[461] C. Tortorella,et al. Arginine-Vasopressin Stimulates CRH and ACTH Release by Rat Adrenal Medulla, Acting Via the V1 Receptor Subtype and a Protein Kinase C-Dependent Pathway , 1997, Peptides.
[462] M. Altemus,et al. Chronic fluoxetine treatment reduces hypothalamic vasopressin secretion in vitro , 1992, Brain Research.
[463] N. Dulin,et al. The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. , 1997, Endocrinology.
[464] G. Nussdorfer,et al. In-vitro and in-vivo studies of the effects of arginine-vasopressin on the secretion and growth of rat adrenal cortex. , 1995, Histology and histopathology.
[465] C. Azuma,et al. Molecular characterization of a cloned human oxytocin receptor. , 1994, European journal of endocrinology.
[466] K. Longo,et al. Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide. , 1998, Cancer research.
[467] Mark J. Zylka,et al. A Molecular Mechanism Regulating Rhythmic Output from the Suprachiasmatic Circadian Clock , 1999, Cell.
[468] H. Albers,et al. Arginine‐vasopressin and the regulation of aggression in female Syrian hamsters (Mesocricetus auratus) , 2010, The European journal of neuroscience.
[469] S. Reppert,et al. Vasopressin exhibits a rhythmic daily pattern in cerebrospinal fluid but not in blood. , 1981, Science.
[470] B. Dunning,et al. Modulation of insulin and glucagon secretion from the perfused rat pancreas by the neurohypophysial hormones and by desamino-D-arginine vasopressin (DDAVP) , 1984, Peptides.
[471] R. Ravid,et al. Localisation of oxytocin, vasopressin and parts of precursors in the human neonatal adrenal , 2004, Histochemistry.
[472] V. Boulay,et al. V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH. , 2012, Molecular endocrinology.
[473] Tomoaki Tanaka,et al. A possible association between aldosterone response to vasopressin and circadian change of aldosterone in the patients with aldosterone-producing adenoma , 2008, Peptides.
[474] Tao Yang,et al. Effects of Nonpeptide V1 Vasopressin Receptor Antagonist SR-49059 on Infarction Volume and Recovery of Function in a Focal Embolic Stroke Model , 2002, Stroke.
[475] G. Griebel,et al. Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals. , 2003, Stress.
[476] J. Peters,et al. The Vasopressin System: Physiology and Clinical Strategies , 2006, Anesthesiology.
[477] D. Jezova,et al. Repeated stress-induced activation of corticotropin-releasing factor neurons enhances vasopressin stores and colocalization with corticotropin-releasing factor in the median eminence of rats. , 1991, Neuroendocrinology.
[478] S. Phelps,et al. Variation in neural V1aR predicts sexual fidelity and space use among male prairie voles in semi-natural settings , 2008, Proceedings of the National Academy of Sciences.
[479] R. Star,et al. Intranephron localization and regulation of the V1a vasopressin receptor during chronic metabolic acidosis and dehydration in rats , 2001, Pflügers Archiv.
[480] J. Gádoros,et al. Evidence of an association between the vasopressin V1b receptor gene (AVPR1B) and childhood-onset mood disorders. , 2007, Archives of general psychiatry.
[481] R. Kahn,et al. Selective impairments in the stress response in schizophrenic patients , 2000, Psychopharmacology.
[482] L. Rodrigues,et al. The influence of vasopressin and related peptides on glycogen phosphorylase activity and phosphatidylinositol metabolism in hepatocytes. , 1979, The Biochemical journal.
[483] O. Manzoni,et al. Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. , 1995, Endocrinology.
[484] D. Cook,et al. Intracellular ATP directly blocks K+ channels in pancreatic B-cells , 1984, Nature.
[485] I. Neumann,et al. Brain vasopressin is an important regulator of maternal behavior independent of dams' trait anxiety , 2008, Proceedings of the National Academy of Sciences.
[486] F. Morel,et al. Vasopressin dependent adenylate cyclase in single segments of rabbit kidney tubule , 1975, Pflügers Archiv.
[487] C. S. Gal,et al. The Discovery of Novel Vasopressin V1b Receptor Ligands for Pharmacological, Functional and Structural Investigations , 2004, Journal of neuroendocrinology.
[488] G. J. de Vries,et al. Vasopressin innervation of the mouse (Mus musculus) brain and spinal cord , 2011, The Journal of comparative neurology.
[489] Michel Bouvier,et al. Oligomerization of G-protein-coupled transmitter receptors , 2001, Nature Reviews Neuroscience.
[490] A. Rofe,et al. Metabolic effects of vasopressin infusion in the starved rat. Reversal of ketonaemia. , 1983, The Biochemical journal.
[491] F. Ciruela,et al. G‐protein‐coupled receptor heteromers: function and ligand pharmacology , 2008, British journal of pharmacology.
[492] George Paxinos,et al. The Mouse Brain in Stereotaxic Coordinates , 2001 .
[493] Michel Bouvier,et al. Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[494] G. Aguilera,et al. Vasopressinergic regulation of the hypothalamic–pituitary–adrenal axis: implications for stress adaptation , 2000, Regulatory Peptides.
[495] H. Bruining,et al. Vasopressin deficiency contributes to the vasodilation of septic shock. , 1998, Circulation.
[496] K. Furuichi,et al. Evidence that atypical vasopressin V(2) receptor in inner medulla of kidney is V(1B) receptor. , 2000, European journal of pharmacology.
[497] Jerrold S. Meyer,et al. Principles of Neuropsychopharmacology , 1997 .
[498] Michael J. Brownstein,et al. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus , 1992, Nature.
[499] J. Lehoux,et al. Vasopressin: a potent growth factor in adrenal glomerulosa cells in culture. , 1984, Journal of steroid biochemistry.
[500] H. Munro,et al. Ntau-methylhistidine (3-methylhistidine) and muscle protein turnover: an overview. , 1978, Federation proceedings.
[501] A. Guyton,et al. Interaction of Vasopressin and the Baroreceptor Reflex System in the Regulation of Arterial Blood Pressure in the Dog , 1974, Circulation research.
[502] G. Griebel,et al. The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice , 2011, Pharmacology Biochemistry and Behavior.
[503] R. Rosenfeld. Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[504] G. Guillon,et al. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. , 2008, Progress in brain research.
[505] W. Ruwe,et al. Thermoregulatory actions of centrally-administered vasopressin in the rat , 1986, Neuropharmacology.
[506] A. Marmarou,et al. Protective effect of the V1a receptor antagonist SR49059 on brain edema formation following middle cerebral artery occlusion in the rat. , 2006, Acta neurochirurgica. Supplement.
[507] M. Shoham,et al. Molecular pharmacology and modeling of vasopressin receptors. , 2002, Progress in brain research.
[508] R. Landgraf,et al. Maternal Behaviour is Associated with Vasopressin Release in the Medial Preoptic Area and Bed Nucleus of the Stria Terminalis in the Rat , 2010, Journal of neuroendocrinology.
[509] H. Sitter,et al. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. , 2004, The New England journal of medicine.
[510] Eric Reiter,et al. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. , 2006, Trends in endocrinology and metabolism: TEM.
[511] C. Carter,et al. Sex differences in oxytocin and vasopressin: Implications for autism spectrum disorders? , 2007, Behavioural Brain Research.
[512] D. Dluzen,et al. Olfactory bulb norepinephrine depletion abolishes vasopressin and oxytocin preservation of social recognition responses in rats , 1998, Neuroscience Letters.
[513] Geenen,et al. Review Article Thymic Expression of Neuroendocrine Self‐Peptide Precursors: Role in T Cell Survival and Self‐Tolerance , 1998, Journal of neuroendocrinology.
[514] G. Makara,et al. Glutamate agonists activate the hypothalamic–pituitary–adrenal axis through hypothalamic paraventricular nucleus but not through vasopressinerg neurons , 2005, Brain Research.
[515] G. Tsujimoto,et al. Effects of vasopressin V1b receptor deficiency on adrenocorticotropin release from anterior pituitary cells in response to oxytocin stimulation. , 2008, Endocrinology.
[516] K. Tomita,et al. Low pH stimulates vasopressin V2 receptor promoter activity and enhances downregulation induced by V1a receptor stimulation. , 2009, American journal of physiology. Renal physiology.
[517] A. Tanoue,et al. Enhanced effect of neuropeptide Y on food intake caused by blockade of the V(1A) vasopressin receptor. , 2009, European journal of pharmacology.
[518] M. Brownstein,et al. Molecular Biology of Vasopressin Receptors , 1995, Annals of the New York Academy of Sciences.
[519] S. Israel,et al. Association between arginine vasopressin 1a receptor (AVPR1a) promoter region polymorphisms and prepulse inhibition , 2009, Psychoneuroendocrinology.
[520] E. D. de Kloet,et al. Oxytocin receptors in the rat thymic gland. , 1988, European journal of pharmacology.
[521] Keshava Rajagopal,et al. Teaching old receptors new tricks: biasing seven-transmembrane receptors , 2010, Nature Reviews Drug Discovery.
[522] C. S. Gal,et al. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. , 2005, Current pharmaceutical design.
[523] B. Ahrén,et al. G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes. , 2007, Pharmacology & therapeutics.
[524] A. Austin,et al. Vasopressin in liver disease--should we turn on or off? , 2008, Current clinical pharmacology.
[525] Y. Oiso,et al. Osmoregulation of Plasma Vasopressin in Diabetes Mellitus with Sustained Hyperglycemia , 1996, Journal of neuroendocrinology.
[526] M. Oz,et al. Vasopressin deficiency contributes to the vasodilation of septic shock. , 1997, Circulation.
[527] Larry J. Young,et al. Enhanced partner preference in a promiscuous species by manipulating the expression of a single gene , 2004, Nature.
[528] C. S. Gal,et al. The vasopressin V1b receptor as a therapeutic target in stress-related disorders. , 2003, Current drug targets. CNS and neurological disorders.
[529] K. Mori,et al. Structure and expression of a human oxytocin receptor , 1992, Nature.
[530] N. Swerdlow,et al. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges , 2001, Psychopharmacology.
[531] T. Laudański,et al. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women , 1999, British journal of obstetrics and gynaecology.
[532] A. Takeshita,et al. Biphasic forearm vascular responses to intraarterial arginine vasopressin. , 1989, The Journal of clinical investigation.
[533] C. Kamei,et al. Effects of metabolic fragments of [Arg8]-vasopressin on nerve growth in cultured hippocampal neurons , 2000, Brain Research Bulletin.
[534] C. Broekkamp,et al. Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. , 1986, European journal of pharmacology.
[535] A. Baertschi,et al. A novel type of vasopressin receptor on anterior pituitary corticotrophs? , 1985, Endocrinology.
[536] L. Albizu,et al. Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. , 2007, Journal of medicinal chemistry.
[537] G. Aguilera,et al. Dimerization Between Vasopressin V1b and Corticotropin Releasing Hormone Type 1 Receptors , 2007, Cellular and Molecular Neurobiology.
[538] A. F. Muller,et al. Properties of rat anterior pituitary vasopressin receptors: relation to adenylate cyclase and the effect of corticotropin-releasing factor. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[539] D. Feifel,et al. Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol , 2001, Biological Psychiatry.